TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Treatment of High Blood Pressure
Brief Summary: This study is an NIH-funded clinical trial conducted at Duke Medical Center evaluating the effects of the DASH diet alone and combined with a behavioral weight loss program on blood pressure and various vascular measures. Eligible patients must be unmedicated with blood pressure values ranging from approximately 130/85 to 159/99. Our primary hypothesis are as follows: (1) The DASH diet alone and combined with a behavioral weight management program will result in greater BP reductions than Usual Care controls at the end of the 4 month treatment period; (2) The DASH diet in combination with a behavioral weight management program will be more effective in lowering BP than the DASH diet alone; (3) The DASH diet alone and the DASH diet combined with the behavioral weight management program will result in greater improvements in cardiac, metabolic, and vascular function compared to the control condition; and (4) The combined DASH diet and weight management intervention also will be the most effective treatment in maintaining BP reductions at 1-year follow-up.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: DASH diet; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet | Arm Label: DASH diet plus Weight loss; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet plus Weight loss | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DASH diet; Assigned to Arm(s): DASH diet | Intervention Type: BEHAVIORAL; Name: DASH diet plus Weight loss; Assigned to Arm(s): DASH diet plus Weight loss
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck
Brief Summary: RATIONALE: Surgery may be an effective treatment for oral cancer. It is not yet known whether surgery to remove the tumor and lymph nodes in the neck is more effective than surgery to remove the tumor alone in treating patients with early-stage oral cancer.

PURPOSE: This randomized clinical trial is comparing two types of neck surgery to see how well they work in treating patients with early stage oral cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Selective neck dissection | Arm Label: 2; Type: OTHER; Interventions: Procedure: Conventional Neck dissection | Intervention Type: PROCEDURE; Name: Selective neck dissection; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional Neck dissection; Assigned to Arm(s): 2
B: Arm Label: Standard fractionation RT + cisplatin; Type: OTHER; Interventions: Drug: cisplatin, Radiation: Standard fractionation RT, Procedure: Conventional surgery for select patients | Arm Label: Accelerated fractionation RT + cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Radiation: Accelerated fractionation radiation therapy, Procedure: Conventional surgery for select patients | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Standard fractionation RT; Assigned to Arm(s): Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Accelerated fractionation radiation therapy; Assigned to Arm(s): Accelerated fractionation RT + cisplatin | Intervention Type: PROCEDURE; Name: Conventional surgery for select patients; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fluorescence visualization device | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fluorescence visualization device | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): A
D: Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: regional lymph node dissection; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dortmund Intervention Trial for Optimization of Infant Nutrition
Brief Summary: The objective of this study is to determine the influence of an increase of meat in complementary food on iron status and the effect of an exchange of vegetable oil in the same food on the status of omega-3 fatty acids in infants in the second six months of life.


Options:
A: Arm Label: Traditional Diet; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cereal; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Caterpillar Cereal | Intervention Type: DIETARY_SUPPLEMENT; Name: Caterpillar Cereal; Assigned to Arm(s): Cereal
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Egg supplementation | Intervention Type: OTHER; Name: Egg supplementation; Assigned to Arm(s): Treatment
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
D: Arm Label: Babyfood with usual meat content and corn oil; Type: ACTIVE_COMPARATOR; Interventions: Other: more meat and a vegetable oil rich in omega-3 fatty acids, Other: Babyfood with usual meat content and corn oil | Arm Label: more meat and a vegetable oil rich in omega-3 fatty acids; Type: EXPERIMENTAL; Interventions: Other: more meat and a vegetable oil rich in omega-3 fatty acids, Other: Babyfood with usual meat content and corn oil | Intervention Type: OTHER; Name: more meat and a vegetable oil rich in omega-3 fatty acids; Assigned to Arm(s): Babyfood with usual meat content and corn oil, more meat and a vegetable oil rich in omega-3 fatty acids | Intervention Type: OTHER; Name: Babyfood with usual meat content and corn oil; Assigned to Arm(s): Babyfood with usual meat content and corn oil, more meat and a vegetable oil rich in omega-3 fatty acids

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should the Surgeon or the General Practitioner (GP) Follow up Patients After Surgery for Colon Cancer? A Randomized Controlled Trial Focusing on Quality of Life, Cost-effectiveness and Serious Clinical Events.
Brief Summary: The purpose of this study is to clarify cost effectiveness and quality of life issues among colon cancer patients followed up in a hospital setting or by their GP's.Statement of study hypothesis:Postoperative follow up of colon cancer patients (according to national guidelines) by general practitioners will not have any influence on patients' quality of life. There will not be observed any increase in serious clinical events and cost effectiveness will be improved.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Intervention Type: OTHER; Name: ca coli follow-up by GP; Assigned to Arm(s): 1, 2
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Reduced follow-up schedule | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Reduced follow-up schedule; Assigned to Arm(s): Intervention
C: Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch
D: Arm Label: PCI Group; Type: OTHER; Interventions: Other: Patient Concerns Inventory | Arm Label: Non PCI Group; Type: OTHER; Interventions: Other: No Patient Concerns Inventory | Intervention Type: OTHER; Name: Patient Concerns Inventory; Assigned to Arm(s): PCI Group | Intervention Type: OTHER; Name: No Patient Concerns Inventory; Assigned to Arm(s): Non PCI Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should the Surgeon or the General Practitioner (GP) Follow up Patients After Surgery for Colon Cancer? A Randomized Controlled Trial Focusing on Quality of Life, Cost-effectiveness and Serious Clinical Events.
Brief Summary: The purpose of this study is to clarify cost effectiveness and quality of life issues among colon cancer patients followed up in a hospital setting or by their GP's.Statement of study hypothesis:Postoperative follow up of colon cancer patients (according to national guidelines) by general practitioners will not have any influence on patients' quality of life. There will not be observed any increase in serious clinical events and cost effectiveness will be improved.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Intervention Type: OTHER; Name: ca coli follow-up by GP; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A
C: Arm Label: 1 frequent control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CT-scan, CEA, X-ray of lungs | Arm Label: 2 less frequent control; Type: OTHER; Interventions: Procedure: CT-scan, CEA, X-ray of lungs | Intervention Type: PROCEDURE; Name: CT-scan, CEA, X-ray of lungs; Assigned to Arm(s): 1 frequent control | Intervention Type: PROCEDURE; Name: CT-scan, CEA, X-ray of lungs; Assigned to Arm(s): 2 less frequent control
D: Arm Label: minimal surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Arm Label: intensive surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Intervention Type: OTHER; Name: surveillance program after completion of primary treatment; Assigned to Arm(s): intensive surveillance, minimal surveillance

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Co-morbid Obesity and Major Depressive Disorder
Brief Summary: This study will compare the effectiveness of two weight loss programs, one supplemented with health education and the other supplemented with behavioral counseling, in treating women who are depressed and overweight.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Regular aerobic physical exercise | Arm Label: 2; Type: OTHER; Interventions: Dietary Supplement: Micronutrients | Arm Label: 3; Type: OTHER; Interventions: Behavioral: Regular aerobic physical exercise, Dietary Supplement: Micronutrients | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Activities of daily living + placebo | Intervention Type: BEHAVIORAL; Name: Regular aerobic physical exercise; Assigned to Arm(s): 1, 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrients; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: Activities of daily living + placebo; Assigned to Arm(s): 4
B: Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss treatment, Behavioral: Health education counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss treatment, Behavioral: Behavior therapy for depression | Intervention Type: BEHAVIORAL; Name: Weight loss treatment; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Behavior therapy for depression; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Health education counseling; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Brief Summary: Aprepitant is currently approved for prophylaxis of acute and delayed CINV for highly emetogenic chemotherapy regimens, including cisplatin; however, it has not yet been studied in multiple-day chemotherapy treatment programs. This study will compare the addition of aprepitant compared to placebo administered on days 3,4,5 of chemotherapy administration for acute CINV prophylaxis with standard antiemetic prophylaxis and days 6 and 7 for delayed CINV prophylaxis in a double-blind, randomized, crossover study design.


Options:
A: Arm Label: Arm A: Aprepitant, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant, Drug: Placebo | Arm Label: Arm B: Placebo, Then Aprepitant; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant, Drug: Placebo | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Arm A: Aprepitant, Then Placebo, Arm B: Placebo, Then Aprepitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm A: Aprepitant, Then Placebo, Arm B: Placebo, Then Aprepitant
B: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Placebo, Drug: Ondansetron | Arm Label: Single Dose IV; Type: EXPERIMENTAL; Interventions: Drug: Casopitant, Drug: Dexamethasone, Drug: Ondansetron | Intervention Type: DRUG; Name: Casopitant; Assigned to Arm(s): Single Dose IV | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Control, Single Dose IV | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Control, Single Dose IV
C: Arm Label: Standard therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Aprepitant / Fosaprepitant therapy; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant / Fosaprepitant | Intervention Type: DRUG; Name: Aprepitant / Fosaprepitant; Assigned to Arm(s): Aprepitant / Fosaprepitant therapy
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Emend | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Emend; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects With Lupus Nephritis in Combination With Mycophenolate Mofetil Therapy.
Brief Summary: The purpose of this study is to learn whether atacicept treatment leads to improvement in kidney function in subjects with active lupus nephritis in combination with mycophenolate mofetil (MMF) and corticosteroids. The study was sponsored by Merck Serono International; operational oversight was provided by ZymoGenetics.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: abatacept, Drug: cyclophosphamide, Drug: azathioprine, Drug: prednisone, Drug: azathioprine placebo | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: azathioprine, Drug: prednisone, Drug: abatacept placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: abatacept placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: azathioprine placebo; Assigned to Arm(s): Treatment
B: Arm Label: Atacicept Plus Mycophenolate mofetil Plus Corticosteroids; Type: EXPERIMENTAL; Interventions: Drug: Atacicept, Drug: Mycophenolate mofetil, Drug: Corticosteroids | Arm Label: Placebo Plus Mycophenolate mofetil Plus Corticosteroids; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mycophenolate mofetil, Drug: Placebo, Drug: Corticosteroids | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept Plus Mycophenolate mofetil Plus Corticosteroids | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Atacicept Plus Mycophenolate mofetil Plus Corticosteroids, Placebo Plus Mycophenolate mofetil Plus Corticosteroids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Plus Mycophenolate mofetil Plus Corticosteroids | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Atacicept Plus Mycophenolate mofetil Plus Corticosteroids, Placebo Plus Mycophenolate mofetil Plus Corticosteroids
C: Arm Label: CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO 136; Assigned to Arm(s): CNTO 136 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus | Arm Label: mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Migraine Pain, Studies 1 and 2 of 2
Brief Summary: Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Studies 1 and 2 of 2)


Options:
A: Arm Label: TPB; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: TBP; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: BTP; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: BPT; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: PTB; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: PBT; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Intervention Type: DRUG; Name: TREXIMET®; Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB | Intervention Type: DRUG; Name: Butalbital-containing Combination Medications (BCM); Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB
B: Intervention Type: DRUG; Name: sumatriptan succinate/naproxen sodium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: sumatriptan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naproxen sodium; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: sumatriptan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naproxen sodium; Assigned to Arm(s): N/A

Answer: A